Inotuzumab ozogamicin, a nonchemotherapy option for relapsed acute lymphoblastic leukemia

Hagop M. Kantarjian

Inotuzumab ozogamicin, a nonchemotherapy option for relapsed acute lymphoblastic leukemia

Leukemia

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	268-270
Number of pages	3
Journal	Clinical Advances in Hematology and Oncology
Volume	17
Issue number	5
State	Published - May 2019

ASJC Scopus subject areas

Hematology
Oncology

Cite this

@article{d182e1ca7aae4bfba9e2e96ea27fe518,

title = "Inotuzumab ozogamicin, a nonchemotherapy option for relapsed acute lymphoblastic leukemia",

author = "Kantarjian, {Hagop M.}",

note = "Funding Information: Dr Kantarjian has received research grants from AbbVie, Agios, Amgen, Ariad, Astex, BMS, Cyclacel, Daiichi Sankyo, Immunogen, Jazz Pharma, Novartis, and Pfizer. He has received honoraria from AbbVie, Actinium, Agios, Amgen, Immunogen, Orsinex, Pfizer, and Takeda.",

year = "2019",

month = may,

language = "English (US)",

volume = "17",

pages = "268--270",

journal = "Clinical Advances in Hematology and Oncology",

issn = "1543-0790",

publisher = "Millennium Medical Publishing, Inc.",

number = "5",

}

TY - JOUR

T1 - Inotuzumab ozogamicin, a nonchemotherapy option for relapsed acute lymphoblastic leukemia

AU - Kantarjian, Hagop M.

N1 - Funding Information: Dr Kantarjian has received research grants from AbbVie, Agios, Amgen, Ariad, Astex, BMS, Cyclacel, Daiichi Sankyo, Immunogen, Jazz Pharma, Novartis, and Pfizer. He has received honoraria from AbbVie, Actinium, Agios, Amgen, Immunogen, Orsinex, Pfizer, and Takeda.

PY - 2019/5

Y1 - 2019/5

UR - http://www.scopus.com/inward/record.url?scp=85068112041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068112041&partnerID=8YFLogxK

M3 - Article

C2 - 31188803

AN - SCOPUS:85068112041

SN - 1543-0790

VL - 17

SP - 268

EP - 270

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

IS - 5

ER -

Inotuzumab ozogamicin, a nonchemotherapy option for relapsed acute lymphoblastic leukemia

ASJC Scopus subject areas

Other files and links

Cite this